ERBB2 and non-small cell lung carcinoma: Depending on the mutation type and concomitant genomic aberrations, other anti-HER2 drugs, such as afatinib, a pan-HER inhibitor, have moderate efficacy in NSCLC patients with HER2 mutations (7, 8).